David Gerhold
Papers
1
Total Citations
49
H-Index
1
About
Dr. David Gerhold is a pioneering figure in the field of in vitro toxicology and high-throughput screening, with a career dedicated to transforming how chemical safety and drug toxicity are assessed. His seminal work, including the highly cited 2023 review "High-Throughput Screening to Advance In Vitro Toxicology: Accomplishments, Challenges, and Future Directions" (49 citations), synthesizes the shift from traditional, low-throughput animal studies to advanced cell-based assays. Dr. Gerhold’s major contributions lie in developing and validating scalable screening platforms that predict human toxicity earlier in the drug development pipeline, reducing reliance on costly and ethically complex animal models. His research has directly addressed the critical need for faster, cheaper, and more human-relevant toxicity testing, impacting both regulatory science and pharmaceutical R&D. With a career spanning decades, his work has influenced the adoption of high-throughput approaches by agencies like the EPA and NIH, and his insights continue to guide the integration of omics technologies and computational modeling into toxicology. Dr. Gerhold’s legacy is one of innovation, pushing the field toward more predictive, efficient, and humane safety assessments.
Research Focus
Key Achievements
Top Papers
- 1